DNAJC12 and dopa-responsive nonprogressive parkinsonism

Ann Neurol. 2017 Oct;82(4):640-646. doi: 10.1002/ana.25048. Epub 2017 Oct 11.

Abstract

Biallelic DNAJC12 mutations were described in children with hyperphenylalaninemia, neurodevelopmental delay, and dystonia. We identified DNAJC12 homozygous null variants (c.187A>T;p.K63* and c.79-2A>G;p.V27Wfs*14) in two kindreds with early-onset parkinsonism. Both probands had mild intellectual disability, mild nonprogressive, motor symptoms, sustained benefit from small dose of levodopa, and substantial worsening of symptoms after levodopa discontinuation. Neuropathology (Proband-A) revealed no alpha-synuclein pathology, and substantia nigra depigmentation with moderate cell loss. DNAJC12 transcripts were reduced in both patients. Our results suggest that DNAJC12 mutations (absent in 500 early-onset patients with Parkinson's disease) rarely cause dopa-responsive nonprogressive parkinsonism in adulthood, but broaden the clinical spectrum of DNAJC12 deficiency. Ann Neurol 2017;82:640-646.

MeSH terms

  • Adult
  • Amyloid beta-Peptides / metabolism
  • Antiparkinson Agents / therapeutic use*
  • Biogenic Amines / metabolism
  • Brain / metabolism
  • Brain / pathology
  • DNA Mutational Analysis
  • DNA-Binding Proteins / metabolism
  • Family Health
  • Female
  • Humans
  • Levodopa / therapeutic use*
  • Male
  • Middle Aged
  • Mutation / genetics*
  • Parkinsonian Disorders / drug therapy*
  • Parkinsonian Disorders / genetics*
  • Parkinsonian Disorders / pathology
  • Phenylalanine / metabolism
  • Repressor Proteins / genetics*
  • Sequestosome-1 Protein / metabolism
  • Young Adult
  • alpha-Synuclein / metabolism
  • tau Proteins / metabolism

Substances

  • Amyloid beta-Peptides
  • Antiparkinson Agents
  • Biogenic Amines
  • DNA-Binding Proteins
  • DNAJC12 protein, human
  • Repressor Proteins
  • SQSTM1 protein, human
  • Sequestosome-1 Protein
  • TARDBP protein, human
  • alpha-Synuclein
  • tau Proteins
  • Levodopa
  • Phenylalanine